Overview
Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.
You can access the company’s website by clicking here.
Research History
-
25 Jun 2020 10 min read
Sareum Holdings – Potential strategy in COVID-19
Potential strategy in COVID-19 The SARS-Cov-2 pandemic presents Sareum with an unexpected opportunity to test its lead TYK2 inhibitor, SDC-1801, in COVID-19. Such a move would require external funding, but could accelerate clinical development timelines and catalyse a substantial increase in value. Meanwhile, the recent £1m fundraising allows Sareum to advance SDC-1801 towards trials for […]
-
10 min read
Sareum Holdings – Potential strategy in COVID-19
Potential strategy in COVID-19 The pandemic presents Sareum with an unexpected opportunity to test its lead TYK2 inhibitor, SDC-1801, in COVID-19. Such a move would require external funding, but this could accelerate clinical development timelines and catalyse a substantial increase in value for the company. Meanwhile, the recent £1m fundraising allows Sareum to advance SDC-1801 […]
-
10 Dec 2019 13 min read
Sareum Holdings – Tyking over… nicely
Table of contents Tyking over…nicely Data summary Investment summary Company profile: Virtual development TYK2 – autoimmune disease SRA737 development affected by Sierra’s strategic change Investment thesis – valuation Stock catalysts Investment sensitivities Management & shareholders Financials Appendix – JAK licensing deals Previous publications The legal bit Tyking over… nicely Sareum’s investment case centres on the […]
-
12 min read
Sareum Holdings – Tyking over… nicely
Tyking over… nicely Sareum’s core investment proposition is focused on the development and potential out-licensing of its two internal, preclinical-stage TYK2/JAK1 inhibitors, which are proceeding towards IND filings in 2020. Development of the Sareum-originated Chk1 inhibitor, SRA737, is, however, likely to enter a state of abeyance, while partner Sierra Oncology attempts to secure a sub-licensing […]
-
08 May 2019 3 min read
QuotedData’s investment companies roundup – May 2019
Investment Companies Roundup New research Over April, we published notes on Henderson Diversified Income, Ecofin Global Utilities and Infrastructure, Jupiter Emerging and Frontier Income, Seneca Global Income & Growth and Polar Capital Global Financials Trust. You can read all these notes by clicking on the links above or by visiting www.quoteddata.com. In this issue Performance data – it was […]
-
21 Mar 2019 1 min read
Sareum Holdings – Key ‘737 data coming up
Sareum’s investment case stands on two pillars: the development by licensee Sierra Oncology of the Chk1 inhibitor, SRA737; and the development and potential licensing of internally-generated TYK2 candidates for autoimmune disease and cancer. This year should see the first clinical data on SRA737, as well as further data from preclinical studies, that may support a […]
-
1 min read
Sareum Holdings – Key ‘737 data coming up
Sareum’s investment case stands on two pillars: the development by licensee Sierra Oncology of the Chk1 inhibitor, SRA737; and the development and potential licensing of internally-generated TYK2 candidates for autoimmune disease and cancer. This year should see the first clinical data on SRA737, as well as further data from preclinical studies, that may support a […]
-
07 Nov 2018 1 min read
Sareum Holdings – TYKing the boxes
Sareum Holdings – TYKing the boxes Sareum’s investment case centres on the development of the Chk1 inhibitor, SRA737, in solid tumours, by its licensee and on the internal development and potential licensing of internally-generated TYK2 candidates for autoimmune disease and cancer. Marten & Co values Sareum’s 27.5% economic interest in the licensing deal covering SRA737 […]
-
1 min read
Sareum Holdings – TYKing the boxes
Sareum Holdings – TYKing the boxes Sareum Holdings’ (Sareum’s) investment case centres on the development of a therapy for the treatment of solid tumours (SRA737, a Chk1 inhibitor – see page 6 for an explanation) and the potential licensing of internally-generated candidates for the treatment of autoimmune disease and cancer (TYK2/JAK1 inhibitors –see page 8). […]
News
-
15 Jul 2019 2 min read
Trust favourite Gilead expands R&D deal with Galapagos
Trust favourite Gilead expands R&D deal with Galapagos – US biotech giant Gilead Sciences (NASDAQ: GILD) has entered into a ten-year R&D collaboration with Galapagos (Euronext/NASDAQ: GLPG) covering rights to the Belgium group’s entire development portfolio. The transformative deal includes a $3.95bn upfront payment – a new record in the industry – as well as $1.1bn in […]
-
02 Jul 2019 2 min read
Gilead confirms plan to file filgotinib this year
Gilead confirms plan to file filgotinib this year – Trust favourite Gilead (NASDAQ: GILD) announced yesterday that it expected to file its closely watched JAK1 inhibitor filgotinib – which is licensed from the Belgian biotech Galapagos (NASDAQ:GLPG) – in the key indication of rheumatoid arthritis (RA) later this year, up to 12 months ahead of the […]
-
28 Jun 2019 1 min read
Sareum raises £0.8m to advance TYK2/JAk1 programmes
Sareum raises £0.8m to advance TYK2/JAk1 programmes Sareum Holdings (SAR) has raised £0.78m through a placing of 195m shares at 0.4p per share, in a move principally designed to progress its TYK2/JAK1 programmes. As a result of the placing, the company will have 3.07bn shares in issue. The funds Sareum to advance its internal programmes – SDC-1801 […]
-
05 Jun 2019 2 min read
InflaRx stock crashes on study failure in HS
InflaRx stock crashes on study failure in HS US-listed German biotech InflaRx (Nasdaq: IFRX) saw its stock fall by 89% earlier today on the failure of a Phase IIb study of its lead product, IFX-1, in moderate to severe hidradenitis suppurativa (HS), a painful and chronic inflammatory skin disease. The study enrolled 179 patients who […]
-
04 Jun 2019 2 min read
Promising early clinical data on Sareum’s SRA737 presented at ASCO
Promising early clinical data on Sareum’s SRA737 presented at ASCO Sierra Oncology, the licence holder for the Sareum (SAR)-originated SRA737, presented positive preliminary data from its two Phase I/II studies at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) conference over the weekend. The poster presentations cover preliminary clinical data from […]
-
22 May 2019 1 min read
Amgen takeover of Nuevolution provides rare valuation for preclin immune/inflam assets
Amgen takeover of Nuevolution provides rare valuation for preclin immune/inflam assets US giant Amgen has announced an agreed takeover offer of SEK1.6bn (c$167m) for Nuevolution, a Swedish biotech, in a move which puts a monetary value of a small number of orally available preclincal assets, mostly in the immune/inflamamtory space. This area has seen relatively few […]
-
30 Apr 2019 1 min read
Sareum to benefit from Lilly decision over competitor product
Sareum (SAR), together with its US-based licensee Sierra Oncology, should be a major beneficiary in competitive terms from an apparent decision by Lilly to discontinue development its Chk1 inhibitor, prexasertib. Sierra has the only other compound with this mechanism in clincial trials and, as a result, its Chk1 inihitibitor, SRA737 – which originated at Sareum […]
-
03 Apr 2019 2 min read
Sareum notes strong preclinical SCLC data on SRA737 at AACR
Sareum (SAR) has noted the presentation by its partner Sierra Oncology of preclinical data showing “profound synergy” for the triple combination of the CHK1 inhibitor SRA737 in combination with low-dose gemcitabine (LDG) and anti-PD-L1 immunotherapy in a mouse model of small cell lung cancer (SCLC). The data were reported in a late-breaking oral presentation at the […]
